Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SEAGEN INC.

(SGEN)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
123.44 USD   -0.42%
11/25Weekly market update : The calm before the storm
MS
11/22Mirati attracts fresh takeover interest - Bloomberg News
RE
11/21Truist Securities Initiates Coverage on Seagen at Hold With $135 Price Target
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
CommuniquÚs de presse de la sociÚtÚ SEAGEN INC.
11/18Seagen Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial S..
AQ
11/11Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy C..
AQ
11/10Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS« (brentuximab vedotin..
BU
11/10Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy C..
BU
11/10Seagen Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
11/10Seagen Appoints Sandra M. Swain, M.D., to Board of Directors
BU
11/10Seagen Names David R. Epstein as Chief Executive Officer and Director
BU
10/28Seagen : Earnings Document
PU
10/27SEAGEN INC. Management's Discussion and Analysis of Financial Condition and Results of..
AQ
10/27Seattle Genetics : Q3 Earnings Snapshot
AQ
10/27Seagen Reports Third Quarter 2022 Financial Results
BU
10/06Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial R..
BU
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
AQ
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
AQ
09/27Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
BU
09/26Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance ..
BU
09/26Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance ..
AQ
09/20Seagen Announces TUKYSA in Combination with Trastuzumab Granted Priority Review by FDA ..
AQ
09/19Seagen Announces TUKYSA« (tucatinib) in Combination with Trastuzumab Granted Priority R..
BU
09/07Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Soci..
BU
09/07Seagen to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
BU
08/12Seagen : Statement on Outcome of Daiichi Sankyo Arbitration - Form 8-K
PU
08/12Seagen Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/12Seagen Statement on Outcome of Daiichi Sankyo Arbitration
BU
07/28SEAGEN INC. Management's Discussion and Analysis of Financial Condition and Results of..
AQ
07/28Seattle Genetics : Q2 Earnings Snapshot
AQ
07/28Seagen : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
07/28Seagen Reports Second Quarter 2022 Financial Results
BU
07/27Astellas and Seagen Announce Positive Topline Results For PADCEV (enfortumab vedotin-ej..
AQ
07/26Seagen : and Astellas Announce Positive Topline Results For PADCEV« (enfortumab vedotin-ej..
PU
07/26Seagen Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/26Seagen and Astellas Announce Positive Topline Results For PADCEV« (enfortumab vedotin-e..
BU
07/25The Other Side Of The Coin : Diligent Patent Prosecution Does Not Lead To Unreasonable Del..
AQ
07/19Daiichi Sankyo Co., Ltd. - U.S. Patent Office Issues Decision on Seagen's Rehearing Req..
AQ
07/18Goldman Sachs, ODP, Boeing rise; Seagen falls
AQ
07/08Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2022 Financial ..
BU
07/07GameStop, Occidental rise; USANA, Helen of Troy fall
AQ
07/02Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meanin..
BU
06/17Adobe, Devon Energy fall; Moderna, Seagen rise
AQ
06/07Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Pro..
AQ
06/06Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK«) Clinical Development Pr..
BU
06/06Seagen Inc. - ADCETRIS (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonst..
AQ
06/03ADCETRIS« (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superio..
BU
06/01Seagen : Management Change/Compensation - Form 8-K/A
PU
06/01SEAGEN INC. Change in Directors or Principal Officers (form 8-K/A)
AQ
05/23Seagen : Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA« (..
PU
05/23Seagen Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/23Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA« ..
BU
05/19Seagen Inc. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16Seagen Inc. : Change in Directors or Principal Officers, Financial Statements and Exhibits..
AQ
05/16Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
BU
05/09Seagen Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
05/09Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
BU
04/28Seagen : Reports First Quarter 2022 Financial Results - Form 8-K
PU
04/28SEAGEN INC. Management's Discussion and Analysis of Financial Condition and Results of..
AQ
04/28Seattle Genetics : Q1 Earnings Snapshot
AQ
04/28Seagen Reports First Quarter 2022 Financial Results
BU
04/28Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of ..
BU
04/20Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support..
BU
04/15Seagen Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial S..
AQ
04/13European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or..
BU
04/08Seagen : Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo - Form 8-..
PU
04/08Seagen Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/08Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo
BU
04/08Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug..
BU
04/07Seagen to Host Conference Call and Webcast Discussion of First Quarter 2022 Financial R..
BU
03/11Seagen Inc. : Change in Directors or Principal Officers, Financial Statements and Exhibits..
AQ
03/01Seagen to Present at the Cowen 42nd Annual Health Care Conference
BU
02/28Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortum..
BU
02/14Astellas and Seagen Announce Initial Results of PADCEV« (enfortumab vedotin-ejfv) in Pa..
PR
02/09SEAGEN INC. Management's Discussion and Analysis of Financial Condition and Results of..
AQ
02/09Seattle Genetics : Q4 Earnings Snapshot
AQ
02/09Seagen : Reports Fourth Quarter and Full Year 2021 Financial Results - Form 8-K
PU
02/09Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
BU
02/08Seagen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
BU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on SEAGEN INC.